Immunome Issues Inducement Equity Grants
BOTHELL, Wash., Feb. 6, 2026 — Immunome, Inc., a clinical-stage biotechnology company developing targeted oncology therapeutics, announced that its...
oncology pipeline
Advertisement
FDA Clears PRD-101 Nano Cancer Drug for Phase 1
SEONGNAM, South Korea, Feb. 6, 2026 — PharmaResearch Co., Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Decoy Therapeutics Highlights AI Antiviral Platform
CAMBRIDGE, Mass. & HOUSTON, Feb. 5, 2026 — Decoy Therapeutics, Inc., a preclinical-stage biotechnology company developing next-generation peptide conjugate...
Third Arc Bio Secures $52M to Advance Antibody Pipeline
SPRING HOUSE, Pa., Feb. 4, 2026 — Clinical-stage biotechnology company Third Arc Bio announced the closing of a $52...
FDA Breakthrough Status for Lilly’s Sofetabart Mipitecan ADC
Indianapolis, January 20, 2026 — Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has...
Advertisements
FDA Grants Priority Review to AstraZeneca’s Baxdrostat NDA for Hard-to-Control Hypertension
Cambridge, UK & Wilmington, Delaware, December 2025 — AstraZeneca has announced that the U.S. Food and Drug Administration has...
Formosa Licenses Ophthalmic Clobetasol Suspension to Rxilient for Asia Commercialization
Taipei, Taiwan, December 2025 — Formosa Pharmaceuticals has announced a licensing agreement with Rxilient Biotech to commercialize clobetasol propionate...
Kazia Therapeutics Secures $50M Private Placement to Strengthen Pipeline Funding
Sydney, Australia, December 3, 2025 — Kazia Therapeutics has announced the pricing of a US $50 million private placement...
Innovent Biologics Joins Hang Seng Index, Marking Biopharma Breakthrough
SuZhou, China – Nov. 24, 2025 — Innovent Biologics (01801.HK), a leading Chinese biopharmaceutical company focused on oncology, cardiovascular/metabolic,...
HOOKIPA Completes Sale of HBV and HIV Programs to Gilead Sciences
NEW YORK and VIENNA – October 31, 2025 — HOOKIPA Pharma Inc. (OTC: HOOK) announced the completion of the...
Advertisement
